Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 4/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322780 | 0.88 | TRPM8 (0.49) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6324719 | 0.85 | TRPM8 (0.49) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6322783 | 0.83 | TRPM8 (0.52) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6327342 | 0.80 | TRPM8 (0.49) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6327033 | 0.76 | TRPM8 (0.72) | TRPM8MTNR1AMTNR1BRAF1MAP2K1 | |
| SCHEMBL6648580 | 0.75 | TRPM8 (0.49) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6327346 | 0.75 | TRPM8 (0.51) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL14463914 | 0.75 | TRPM8 (0.60) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 | |
| SCHEMBL6326223 | 0.72 | TRPM8 (0.56) | TRPM8MTNR1AMTNR1BRAF1MAP2K1 | |
| SCHEMBL14078293 | 0.72 | MRGPRX4 (0.52) | TRPM8MTNR1AMTNR1BMRGPRX4RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE | 2005-10-13 | — | — | US | disclosed |
| EP-1442018-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037865-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | TP53, ABCG2, MCL1 | TRPM8 2570/4885MTNR1A 2615/4885MTNR1B 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.